GlobeNewswire Inc | Oct 29, 2020 08:00AM EDT

October 29, 2020

~ Results in line with expectations, Strong cash flow from operations ~~W0:~ Expect beginning of sales recovery and improved profitability in 4Q20 ~~W0:

PLANO, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and nine months ended October 2, 2020. Unless otherwise stated, all results and comparisons are from continuing operations.

Executing strategy through the COVID-19 pandemic

-- Throughout the pandemic, Integer associates continue to deliver critical products that customers and patients rely on every day. -- Integers Manufacturing Excellence strategic imperative continues to deliver results during COVID-19. -- Integer continues to invest in its product line and operational strategy to create long-term value, including manufacturing capabilities and R&D resources.

Third Quarter 2020 Highlights (compared to Third Quarter 2019)

-- The impact of COVID-19 on the third quarter 2020 financial results was consistent with Integers second quarter 2020 earnings communication. -- Sales declined $68 million to $236 million, a decrease of 22%. -- GAAP income was $30 million, a decrease of 1%. Non-GAAP adjusted income declined $23 million to $17 million, a decrease of 58%. -- Adjusted EBITDA declined $33 million to $37 million, a decrease of 47%. -- GAAP diluted EPS was $0.92 per share for both periods. Non-GAAP adjusted diluted EPS decreased $0.70 per share to $0.50 per share, a decrease of 58%. -- Net total debt decreased $23 million from the end of the second quarter 2020 to $747 million. -- The third quarter 2020 GAAP results include a pre-tax gain of $28 million, resulting in an after-tax impact of $0.67 per diluted share from a patent litigation judgment affirmed by the United States Court of Appeals in Integers favor, which are excluded from non-GAAP adjusted results. -- On October 15, 2020 Integer received cash from the patent litigation judgment and paid down an additional $28 million of debt.

Fourth Quarter Outlook

-- Sales are projected to be $20 million to $35 million higher than the third quarter 2020. -- Given the $28 million pre-tax patent litigation judgment gain in the third quarter 2020, GAAP operating income margin is expected to decline in the fourth quarter 2020. -- Adjusted Operating Income margin is projected to be 200 to 300 basis points higher than the third quarter 2020.

Our third quarter results demonstrate improved profitability versus the second quarter, and we expect the fourth quarter to be even stronger, as sales begin to recover from the pandemic and the profit margin rate recovery accelerates, said Joseph Dziedzic, Integers president and chief executive officer. Our Manufacturing Excellence strategic imperative continues to deliver strong operational and financial results. We remain focused on executing our strategy and making the necessary investments to be our customers partner of choice and deliver our financial objectives.

Discussion of Product Line Third Quarter 2020 Sales (compared to Third Quarter 2019)

-- Cardio & Vascular sales decreased 16%. Sales were negatively impacted by the COVID-19 pandemic and a blend of our customers responses across nearly all C&V markets. -- Cardiac & Neuromodulation sales decreased 32%. CRM and Neuromodulation declined commensurate with the COVID-19 pandemic impact and a blend of our customers responses. Additionally, the fourth quarter 2019 Nuvectra bankruptcy created a $3 million headwind. -- Advanced Surgical, Orthopedics & Portable Medical includes sales to the acquirer of our AS&O product line, Viant, under supply agreements entered into as part of the divestiture. Sales declined 12% driven by the COVID-19 pandemic impact and a blend of our customers responses. Portable Medical remained stable while Orthopedics and Advanced Surgical declined. -- Electrochem sales declined 42% driven by a severe decline in the energy market and demand fall-out from the COVID-19 pandemic.

Summary of Financial and Product Line Results from Continuing Operations

(dollars in thousands, except per Three Months Endedshare data) October September OrganicGAAP 2, 27, Change Change^ 2020 2019 (a)Medical Sales Cardio & Vascular $ 124,596 $ 148,581 (16.1 ) % (18.0 ) %Cardiac & Neuromodulation 72,909 106,533 (31.6 ) % (31.6 ) %Advanced Surgical, Orthopedics & 30,179 34,310 (12.0 ) % (12.2 ) %Portable MedicalTotal Medical Sales 227,684 289,424 (21.3 ) % (22.3 ) %Non-Medical Sales 8,258 14,163 (41.7 ) % (41.7 ) %Total Sales $ 235,942 $ 303,587 (22.3 ) % (23.2 ) % Income from continuing operations $ 30,342 $ 30,586 (0.8 ) % (55.6 ) %Diluted EPS from continuing $ 0.92 $ 0.92 ? % (55.5 ) %operations Nine Months Ended October September OrganicGAAP 2, 27, Change Change^ 2020 2019 (a)Medical Sales Cardio & Vascular $ 432,885 $ 451,552 (4.1 ) % (5.3 ) %Cardiac & Neuromodulation 252,404 337,932 (25.3 ) % (25.3 ) %Advanced Surgical, Orthopedics & 92,041 98,544 (6.6 ) % (6.6 ) %Portable MedicalTotal Medical Sales 777,330 888,028 (12.5 ) % (13.1 ) %Non-Medical Sales 27,153 44,429 (38.9 ) % (38.9 ) %Total Sales $ 804,483 $ 932,457 (13.7 ) % (14.3 ) % Income from continuing operations $ 61,831 $ 80,174 (22.9 ) % (39.6 ) %Diluted EPS from continuing $ 1.87 $ 2.43 (23.0 ) % (39.6 ) %operations



Organic Change is a Non-GAAP measure. Please see ?Notes Regarding Non-GAAP^ Financial Information? for additional information regarding our use of(a) non-GAAP financial measures and refer to Table C and Table D at the end of this release for a reconciliation of these amounts.

Three Months Ended October September OrganicNon-GAAP^(a) 2, 27, Change Change^ 2020 2019 (b)Adjusted EBITDA from $ 36,508 $ 69,444 (47.4 ) % (45.9 ) %continuing operationsAdjusted income from $ 16,656 $ 39,575 (57.9 ) % (55.6 ) %continuing operationsAdjusted diluted EPS from $ 0.50 $ 1.20 (58.3 ) % (55.5 ) %continuing operations Nine Months Ended October September YTD OrganicNon-GAAP^(a) 2, 27, Change Change^ 2020 2019 (b)Adjusted EBITDA from $ 140,380 $ 210,497 (33.3 ) % (33.6 ) %continuing operationsAdjusted income from $ 68,425 $ 113,047 (39.5 ) % (39.6 ) %continuing operationsAdjusted diluted EPS from $ 2.07 $ 3.42 (39.5 ) % (39.6 ) %continuing operations



^ Refer to Tables A and B at the end of this release for reconciliations of(a) adjusted amounts to the closest corresponding GAAP financial measures. Organic Change for Adjusted EBITDA from continuing operations, Adjusted income from continuing operations, and Adjusted diluted EPS from continuing^ operations are Non-GAAP measures. Please see ?Notes Regarding Non-GAAP(b) Financial Information? for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.

Conference Call InformationThe Company will host a conference call on Thursday, October 29, 2020, at 9:00 a.m. EDT / 8:00 a.m. CDT to discuss these results. The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (833) 714-0898 (U.S.) or (778) 560-2691 (outside U.S.) and the conference ID is 6778607. The call will be archived on the Companys website. An earnings call slide presentation containing supplemental information about the Companys results will be posted to our website at investor.integer.netprior to the conference call and will be referenced during the conference call.

About IntegerInteger Holdings Corporation(NYSE: ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available atwww.integer.net.

Contact InformationTony BorowiczSVP, Strategy, Business Development & Investor Relations716.759.5809tony.borowicz@integer.net

Notes Regarding Non-GAAP Financial Information

In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (GAAP), we provide adjusted income, adjusted diluted EPS, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted operating income, adjusted operating income margin, adjusted EBITDA, adjusted EBITDA margin, and organic change rates, all from continuing operations. Adjusted income and adjusted diluted EPS from continuing operations consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related expenses, including fair value adjustments to contingent consideration resulting from acquisitions, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain legal expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) (gain) loss on equity investments, (ix) extinguishment of debt charges, (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal provision for the period. Adjusted diluted EPS from continuing operations is calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding. EBITDA from continuing operations is calculated by adding back interest expense, GAAP provision (benefit) for income taxes, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP measure. Adjusted EBITDA from continuing operations consists of EBITDA from continuing operations plus GAAP stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (x) and (xi).

Adjusted operating income from continuing operations consists of GAAP operating income adjusted for the same items listed above except for items (viii), (ix), (x) and (xi). Adjusted operating income margin is adjusted operating income as a percentage of sales, all from continuing operations.

Adjusted EBITDA margin is adjusted EBITDA as a percentage of sales, all from continuing operations. Organic sales change is reported sales growth adjusted for the impact of foreign currency and the contribution of acquisitions. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue, and exclude the amount of sales acquired or divested during the period from the current/previous period amounts, respectively.

Organic change rates for adjusted EBITDA from continuing operations, adjusted income from continuing operations and adjusted diluted EPS from continuing operations exclude the impact of foreign currency exchange gains and losses included in other (income) loss, net, and the contribution of acquisitions. Contribution of acquisitions represents results, based on the growth rate being presented, attributable to acquired entities for the first four full quarters plus any partial period since the entities' acquisition date. After the completion of four full fiscal quarters, results of the acquired entity are treated as organic for current and comparable historical periods.

We believe that the presentation of adjusted income, adjusted diluted EPS, EBITDA, adjusted EBITDA, adjusted EBITDA margin, and organic change rates, all from continuing operations, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.

Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended, including statements relating to the impact of the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy; having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and projected capital spending. You can identify forward-looking statements by terminology such as may, will, should, could, expects, intends, plans, anticipates, believes, estimates, predicts, potential or continue or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: the duration, scope and impact of the COVID-19 pandemic, including government, social, business and other actions taken in response to the pandemic and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our ability to respond to changes in technology; the intense competition we face and our ability to successfully market our products; our ability to develop new products and expand into new geographic and product markets; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability claims; our ability to protect our intellectual property and proprietary rights; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; our ability to integrate acquisitions and operate acquired businesses in accordance with expectations; our dependence upon our senior management team and technical personnel; our ability to realize the benefits from cost savings and consolidation initiatives; interruptions in our manufacturing operations; our ability to comply with environmental regulations; our complex international tax profile; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; market, financial and other risks related to our international operations and sales; global economic factors, including currency exchange rates and interest rates; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; and other risks and uncertainties that arise from time to time and are described in Item1A Risk Factors of our Annual Report on Form 10-K and in our other periodic filings with the SEC. Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Condensed Consolidated Balance Sheets - Unaudited(in thousands) October 2, December 31, 2020 2019ASSETS Current assets: Cash and cash equivalents $ 99,943 $ 13,535 Accounts receivable, net 151,201 191,985 Inventories 156,858 167,256 Contract assets 39,593 24,767 Refundable income taxes 6,521 ? Prepaid expenses and other current assets 44,537 17,852 Total current assets 498,653 415,395 Property, plant and equipment, net 249,982 246,185 Goodwill 851,679 839,617 Other intangible assets, net 759,419 775,784 Deferred income taxes 5,223 4,438 Operating lease assets 46,083 42,379 Other long-term assets 37,956 29,295 Total assets $ 2,448,995 $ 2,353,093 LIABILITIES AND STOCKHOLDERS? EQUITY Current liabilities: Current portion of long-term debt $ 37,500 $ 37,500 Accounts payable 55,397 64,975 Income taxes payable 1,068 3,023 Current portion of lease liabilities 8,287 7,507 Accrued expenses and other current liabilities 51,208 66,073 Total current liabilities 153,460 179,078 Long-term debt 801,607 777,272 Deferred income taxes 188,788 187,978 Operating lease liabilities 39,030 37,114 Other long-term liabilities 33,113 19,163 Total liabilities 1,215,998 1,200,605 Stockholders? equity: Common stock 33 33 Additional paid-in capital 698,654 701,018 Treasury stock ? (8,809 )Retained earnings 502,089 440,258 Accumulated other comprehensive income 32,221 19,988 Total stockholders? equity 1,232,997 1,152,488 Total liabilities and stockholders? equity $ 2,448,995 $ 2,353,093

Condensed Consolidated Statements of Operations - Unaudited(in thousands, except per share data) Three Months Ended Nine Months Ended October 2, September October 2, September 2020 27, 2020 27, 2019 2019Sales $ 235,942 $ 303,587 $ 804,483 $ 932,457 Cost of sales 178,009 210,201 591,985 653,477 Gross profit 57,933 93,386 212,498 278,980 Operating expenses: Selling, general andadministrative expenses 3,609 32,935 73,969 101,034 (SG&A)^(a)Research, development and 11,892 11,729 37,879 34,720 engineering costs (RD&E)Other operating expenses 2,674 2,241 7,631 8,239 (OOE)Total operating expenses 18,175 46,905 119,479 143,993 Operating income 39,758 46,481 93,019 134,987 Interest expense, net 9,368 12,337 29,002 39,779 (Gain) loss on equity (2,234 ) (986 ) (3,954 ) 666 investments, netOther (income) loss, net 1,224 (369 ) (233 ) (921 )Income from continuing 31,400 35,499 68,204 95,463 operations before taxesProvision for income 1,058 4,913 6,373 15,289 taxesIncome from continuing $ 30,342 $ 30,586 $ 61,831 $ 80,174 operations Discontinued operations: Income from discontinued ? ? ? 5,316 operations before taxesProvision for income ? ? ? 178 taxesIncome from discontinued $ ? $ ? $ ? $ 5,138 operations Net income $ 30,342 $ 30,586 $ 61,831 $ 85,312 Basic earnings per share: Income from continuing $ 0.92 $ 0.94 $ 1.88 $ 2.46 operationsIncome from discontinued $ ? $ ? $ ? $ 0.16 operationsBasic earnings per share $ 0.92 $ 0.94 $ 1.88 $ 2.62 Diluted earnings per share:Income from continuing $ 0.92 $ 0.92 $ 1.87 $ 2.43 operationsIncome from discontinued $ ? $ ? $ ? $ 0.16 operationsDiluted earnings per $ 0.92 $ 0.92 $ 1.87 $ 2.58 share Weighted average shares outstanding:Basic 32,859 32,660 32,833 32,606 Diluted 33,076 33,068 33,107 33,019



Selling, general and administrative expenses for the three and nine months^ ended October2, 2020 includes a net gain of $28.2 million recorded during(a) the third quarter of 2020 in connection with the resolution of the AVX Corporation patent litigation matter.

Condensed Consolidated Statements of Cash Flows^(a) - Unaudited(in thousands) Nine Months Ended October 2, September 2020 27, 2019Cash flows from operating activities: Net income $ 61,831 $ 85,312 Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization 59,005 57,397 Debt related charges included in interest expense 3,145 5,280 Stock-based compensation 6,229 6,894 Non-cash charges related to customer bankruptcy 562 ? Non-cash lease expense 5,824 5,555 Non-cash (gain) loss on equity investments (3,954 ) 666 Other non-cash gains (184 ) (1,088 )Deferred income taxes 42 (1,086 )Gain on sale of discontinued operations ? (4,974 )Changes in operating assets and liabilities, net of acquisition:Accounts receivable 42,096 (29,962 )Inventories 10,272 (8,567 )Contract assets, prepaid expenses and other assets (47,350 ) (16,384 )Accounts payable (5,152 ) 17,760 Accrued expenses and other liabilities (13,780 ) (8,988 )Income taxes payable (8,347 ) 4,162 Net cash provided by operating activities 110,239 111,977 Cash flows from investing activities: Acquisition of property, plant and equipment (35,182 ) (24,704 )Purchase of intangible asset (4,607 ) ? Proceeds from sale of property, plant and equipment 76 5 Purchase of equity investments ? (417 )Acquisitions, net (5,219 ) ? Proceeds from sale of discontinued operations ? 4,734 Net cash used in investing activities (44,932 ) (20,382 )Cash flows from financing activities: Principal payments of long-term debt (28,125 ) (97,125 )Proceeds from senior secured revolving line of credit 185,000 20,000 Payments of senior secured revolving line of credit (135,000 ) (25,000 )Proceeds from the exercise of stock options 3,123 2,654 Payment of debt issuance costs (431 ) ? Tax withholdings related to net share settlements of (2,869 ) (2,961 )restricted stock unit awardsNet cash provided by (used in) financing activities 21,698 (102,432 )Effect of foreign currency exchange rates on cash and (597 ) (13 )cash equivalentsNet increase (decrease) in cash and cash equivalents 86,408 (10,850 )Cash and cash equivalents, beginning of period 13,535 25,569 Cash and cash equivalents, end of period $ 99,943 $ 14,719

^ Condensed Consolidated Statements of Cash Flows - Unaudited includes cash(a) flows related to discontinued operations.

Reconciliations of Non-GAAP Measures from Continuing Operations

Table A: Income from Continuing Operations and Diluted EPS Reconciliations(in thousands, except per share amounts)

Three Months Ended October 2, 2020 September 27, 2019 Per Net of Per Pre-Tax Net of Tax Diluted Pre-Tax Tax Diluted Share ShareIncome fromcontinuing $ 31,400 $ 30,342 $ 0.92 $ 35,499 $ 30,586 $ 0.92 operations(GAAP)Adjustments^ (a):Amortization 10,299 8,145 0.25 9,782 7,750 0.23 of intangiblesCertain legalexpenses (27,959 ) (22,089 ) (0.67 ) 99 78 ? (gains) (SG&A)^(b)Otheroperating 2,674 2,070 0.06 2,241 1,710 0.05 expenses (OOE)^(c)Gain on equityinvestments, (2,234 ) (1,764 ) (0.05 ) (986 ) (779 ) (0.02 )netLoss onextinguishment ? ? ? 291 230 0.01 of debtCustomer 341 269 0.01 ? ? ? bankruptcy^(d)Tax ? (317 ) (0.01 ) ? ? ? adjustmentsAdjustedincome fromcontinuing $ 14,521 $ 16,656 $ 0.50 $ 46,926 $ 39,575 $ 1.20 operations(Non-GAAP) Weightedaverage shares 33,076 33,068 for adjusteddiluted EPS Nine Months Ended October 2, 2020 September 27, 2019 Per Net of Per Pre-Tax Net of Tax Diluted Pre-Tax Tax Diluted Share ShareIncome fromcontinuing $ 68,204 $ 61,831 $ 1.87 $ 95,463 $ 80,174 $ 2.43 operations(GAAP)Adjustments^ (a):Amortization 30,894 24,425 0.74 29,467 23,324 0.71 of intangiblesCertain legalexpenses (26,950 ) (21,291 ) (0.64 ) 2,175 1,718 0.05 (gains) (SG&A)^(b)Otheroperating 7,631 5,942 0.18 8,239 6,306 0.19 expenses (OOE)^(c)(Gain) loss onequity (3,954 ) (3,123 ) (0.09 ) 666 526 0.02 investments,netLoss onextinguishment ? ? ? 1,265 999 0.03 of debtCustomer 1,213 958 0.03 ? ? ? bankruptcy^(d)Tax ? (317 ) (0.01 ) ? ? ? adjustmentsAdjustedincome fromcontinuing $ 77,038 $ 68,425 $ 2.07 $ 137,275 $ 113,047 $ 3.42 operations(Non-GAAP) Weightedaverage shares 33,107 33,019 for adjusteddiluted EPS



The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are^ computed using a 21% U.S. tax rate, and the statutory tax rates applicable(a) in foreign tax jurisdictions, as adjusted for the existence of net operating losses (?NOLs?). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%. Represents the net gain of $28.2 million recorded during the third quarter^ of 2020 in connection with the resolution of the AVX Corporation patent(b) litigation matter, as well as expenses associated with non-ordinary course legal matters. Other operating expenses includes acquisition and integration related^ expenses, facility consolidation, optimization, manufacturing transfer and(c) system integration charges, asset write-down and disposition charges, charges in connection with corporate realignments or a reduction in force, unusual or infrequently occurring items. In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the ?Customer Bankruptcy?).^ During the first nine months of 2020, we incurred costs and recorded(d) charges associated with the Customer Bankruptcy, primarily consisting of charges related to inventory recorded in cost of sales in our condensed consolidated statement of operations.

Please see Notes Regarding Non-GAAP Financial Information for additional information regarding our use of non-GAAP financial measures.

Table B: EBITDA Reconciliations(in thousands)

Three Months Ended Nine Months Ended October 2, September October 2, September 2020 27, 2020 27, 2019 2019Income from continuing $ 30,342 $ 30,586 $ 61,831 $ 80,174 operations (GAAP) Interest expense 9,368 12,337 29,002 39,779 Provision for income 1,058 4,913 6,373 15,289 taxesDepreciation 9,632 9,080 28,111 27,930 Amortization of 10,299 9,782 30,894 29,467 intangiblesEBITDA from continuing 60,699 66,698 156,211 192,639 operations (Non-GAAP)Stock-based compensation 2,987 1,392 6,229 6,778 (excluding OOE)Certain legal expenses (27,959 ) 99 (26,950 ) 2,175 (gains)Other operating expenses 2,674 2,241 7,631 8,239 (OOE)(Gain) loss on equity (2,234 ) (986 ) (3,954 ) 666 investments, netCustomer bankruptcy 341 ? 1,213 ? Adjusted EBITDA fromcontinuing operations $ 36,508 $ 69,444 $ 140,380 $ 210,497 (Non-GAAP) Total Sales $ 235,942 $ 303,587 $ 804,483 $ 932,457 Adjusted EBITDA margin 15.5 % 22.9 % 17.4 % 22.6 %

Table C: Organic Sales from Continuing Operations Growth Rate Reconciliation (% Change)

GAAP Impact of Non-GAAP Reported Acquisitions Organic Growth and Foreign Change Currency^(a)QTD Change (3Q 2020 vs. 3Q 2019) Medical Sales Cardio & Vascular (16.1)% (1.9)% (18.0)%Cardiac & Neuromodulation (31.6)% ? (31.6)%Advanced Surgical, Orthopedics & Portable (12.0)% (0.2)% (12.2)%MedicalTotal Medical Sales (21.3)% (1.0)% (22.3)%Non-Medical Sales (41.7)% ? (41.7)%Total Sales (22.3)% (0.9)% (23.2)% YTD Change (9M 2020 vs. 9M 2019) Medical Sales Cardio & Vascular (4.1)% (1.2)% (5.3)%Cardiac & Neuromodulation (25.3)% ? (25.3)%Advanced Surgical, Orthopedics & Portable (6.6)% ?% (6.6)%MedicalTotal Medical Sales (12.5)% (0.6)% (13.1)%Non-Medical Sales (38.9)% ? (38.9)%Total Sales (13.7)% (0.6)% (14.3)%



2020 sales have been adjusted to exclude the contribution of business^ acquisitions and foreign currency exchange rate fluctuations. 2019 sales(a) have been adjusted to exclude the impact of foreign currency exchange rate fluctuations. There was no impact from business acquisitions on the 2019 periods.

Table D: Non-GAAP Organic Growth Rate Reconciliation (% Change)

GAAP Impact of Impact of Non-GAAP Reported Non-GAAP Acquisitions Organic Growth^ Adjustments and Foreign Change (a) ^(b) Currency^(c)QTD Change (3Q 2020 vs. 3Q 2019)EBITDA from continuing (9.0)% (38.4)% 1.5% (45.9)%operationsIncome from continuing (0.8)% (57.1)% 2.3% (55.6)%operationsDiluted EPS from continuing ?% (58.3)% 2.8% (55.5)%operations YTD Change (9M 2020 vs. 9M 2019)EBITDA from continuing (18.9)% (14.4)% (0.3)% (33.6)%operationsIncome from continuing (22.9)% (16.6)% (0.1)% (39.6)%operationsDiluted EPS from continuing (23.0)% (16.5)% (0.1)% (39.6)%operations



^ EBITDA from continuing operations is a non-GAAP financial measure. See(a) Table B for a reconciliation to the most comparable GAAP measure.^ Represents the impact to our growth rate from our Non-GAAP adjustments. See(b) Tables A and B for further detail on these items. Represents the impact to our growth rate due to changes in foreign currency^ exchange rates realized in income and reported in other (income) loss, net(c) in the consolidated statements of operations, and the adjustment to exclude the contribution of acquisitions when applicable.